Immune checkpoint inhibitor related enterocolitis

研究成果: Article査読

抄録

Immune checkpoint inhibitors (ICI) have been rapidly extended their indication in various cancer types. On the other hand, immune-related adverse event (irAE) is observed in some cases and sometime causes fatal outcome. Enterocolitis is one of the major irAE, especially in the case treated with anti-CTLA-4 antibody. Although the combination therapy of anti-CTLA-4 antibody and anti-PD-1 antibody has shown clinical benefit in some cancer types, a risk of enterocolitis is higher than monotherapy. Accumulated evidence has revealed the clinical features of enterocolitis caused by anti-CTLA-4 antibody and anti-PD-1/PD-L1 antibody. We summarize recent knowledge and discuss future perspectives.

本文言語English
ページ(範囲)214-218
ページ数5
ジャーナルJapanese Journal of Cancer and Chemotherapy
47
2
出版ステータスPublished - 2020 2

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究

フィンガープリント

「Immune checkpoint inhibitor related enterocolitis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル